基质金属蛋白酶/基质金属蛋白酶组织抑制剂系统与糖尿病眼部并发症  

Matrix metalloproteinases/tissue inhibitors of metalloproteinase system and diabetic ocular complications

作　　者：任美侠[1] 周健[1] 

机构地区：[1]第四军医大学西京医院眼科全军眼科研究所,西安710032

出　　处：《中华实验眼科杂志》2014年第9期860-864,共5页Chinese Journal Of Experimental Ophthalmology

基　　金：国家自然科学基金项目（30672292）;新世纪优秀人才支持计划项目（NCET-06-932）;西京医院助推计划项目（XJZT09D02）

摘　　要：基质金属蛋白酶/基质金属蛋白酶组织抑制剂（MMPs/TIMPs）系统是降解和重塑细胞外基质（ECM）最重要的酶系统,它参与调节眼的一些生理和病理过程,如眼的发育、炎症、伤口愈合、新生血管形成、肿瘤转移等,与多种眼病,如增生性玻璃体视网膜病变、增生型糖尿病视网膜病变、糖尿病性白内障、孔源性视网膜脱离、视网膜母细胞瘤、年龄相关性黄斑变性、眼外伤、青光跟等的发生密切相关.就MMPs/TIMPs系统的生物学特性及其在糖尿病眼部并发症研究方面的应用进行综述.The matrix metalloproteinases/tissue inhibitors of metalloproteinase （MMPs/TIMPs） system plays an important role in the degradation and remodel of the extracellular matrix （ECM）.MMPs/TIMPs system is associated with ocular physiological process,such as ocular growth and development,etc.Also,MMPs/TIMPs system is involved in ocular pathological process including inflammation,wound healing,neoangiogenesis,tumor invasion and metastasis.MMPs/TIMPs system also participats in the formation of some ophthalmic diseases such as proliferative vitreoretinopathy （PVR）,proliferative diabetic retinopathy （PDR）,diabetic cataract,rhegmatogenous retinal detachment （RRD）,retinoblastoma （RB）,age-related macular degeneration （AMD）,ocular trauma,and glaucoma.This review attempts to elaborate the biological characteristics of MMPs/TIMPs,and the current researches of MMPs/ TIMPs system in the diabetic ocular complications,focusing on diabetic retinopathy,cataract and keratopathy.

关 键 词：基质金属蛋白酶 基质金属蛋白酶组织抑制剂 糖尿病 并发症 视网膜病变 白内障 角膜病变 

分 类 号：R587.2[医药卫生—内分泌]